Angiotensin II regulates anxiety and social-affective top-down and bottom-up attention control in a sex-dependent manner.

J Affect DisordJul 13, 2026 (epub)
Clinical ResearchPsychiatry

Mengfan Han, Kun Fu, Wenyi Dong et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of transient AT1R blockade via losartan (50 mg) on emotional attention control and state anxiety in 79 healthy adults. Losartan reduced state anxiety in both sexes but had sex-dependent effects on attentional control: it improved performance in females while impairing it in males, highlighting the need for sex-specific approaches in treating anxiety disorders.

Key findings

  • Losartan reduced state anxiety in both males and females.
  • In females, losartan decreased endpoint error without changing latency.
  • In males, losartan increased endpoint error and prolonged latency of the first correct saccade.
  • Losartan altered error probabilities based on trial history, with differing effects between sexes.

Why it matters

Understanding the sex-dependent effects of AT1R blockade on anxiety and attentional control can inform tailored therapeutic strategies for anxiety and stress-related disorders, potentially improving treatment outcomes.

Source

PubMed · PMID 42442666

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.